Biotherapy

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 21, Issue 1, 2007, Pages 145-162

  Plockinger U ^a   Wiedenmann, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

biotherapy; interferon; neuroendocrine tumor; somatostatin analog

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; CHENODEOXYCHOLIC ACID; CYANOCOBALAMIN; DIAZOXIDE; GASTRIN; INSULIN; INTERFERON; OCTREOTIDE; PANCREAS ENZYME; PARACETAMOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; URSODEOXYCHOLIC ACID; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; SOMATOSTATIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE HEPATITIS; ALLERGIC REACTION; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; BILIRUBIN BLOOD LEVEL; BLOATING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRADYCARDIA; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CARCINOID SYNDROME; CHOLELITHIASIS; CHOLESTASIS; CYANOCOBALAMIN DEFICIENCY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FATIGUE; FLU LIKE SYNDROME; GALLSTONE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRIN BLOOD LEVEL; GASTRIN RELEASE; GLUCOSE TOLERANCE; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; HYPERLIPIDEMIA; HYPERTHYROIDISM; HYPERTRIGLYCERIDEMIA; HYPOTENSION; IC 50; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INSULIN BLOOD LEVEL; INSULIN RELEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; MENTAL DISEASE; NAUSEA; NEPHROTIC SYNDROME; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PERNICIOUS ANEMIA; PNEUMONIA; PROGNOSIS; QUALITY OF LIFE; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; SKIN ALLERGY; SOLID TUMOR; SOMATOSTATINOMA; STEATORRHEA; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYPHYLAXIS; THROMBOCYTOPENIA; THYROIDITIS; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR REGRESSION; TUMOR VOLUME; VERNER MORRISON SYNDROME; VISUAL DISORDER; VISUAL IMPAIRMENT; VITAMIN BLOOD LEVEL; VOMITING; WEIGHT REDUCTION; ZOLLINGER ELLISON SYNDROME; ACROMEGALY; BIOLOGICAL THERAPY; DOSE RESPONSE;

ACROMEGALY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERONS; NEUROENDOCRINE TUMORS; SOMATOSTATIN;

EID: 33947191600     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2007.01.002     Document Type: Review

References (104)

1. Plockinger U., Rindi G., Arnold R., et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80 6 (2004) 394-424
2. Venkatesh S., Ordonez N.G., Ajani J., et al. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer 65 2 (1990) 354-357
3. Lo C.Y., van Heerden J.A., Thompson G.B., et al. Islet cell carcinoma of the pancreas. World J Surg 20 7 (1996) 878-883 discussion 884
4. Kaltsas G.A., Besser G.M., and Grossman A.B. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25 3 (2004) 458-511
5. Makridis C., Rastad J., Oberg K., et al. Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 20 7 (1996) 900-906 discussion 907
6. Bax N.D., Woods H.F., Batchelor A., et al. Clinical manifestations of carcinoid disease. World J Surg 20 2 (1996) 142-146
7. Moertel C.G. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5 10 (1987) 1502-1522
8. Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg 20 2 (1996) 126-131
9. Modlin I.M., and Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 79 4 (1997) 813-829
10. Caplin M.E., Buscombe J.R., Hilson A.J., et al. Carcinoid tumour. Lancet 352 9130 (1998) 799-805
11. Oberg K. The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am 22 4 (1993) 941-952
12. Oberg K. Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 5 1 (1993) 110-120
13. Ahlman H., Westberg G., Wangberg B., et al. Treatment of liver metastases of carcinoid tumors. World J Surg 20 2 (1996) 196-202
14. Loftus J.P., and van Heerden J.A. Surgical management of gastrointestinal carcinoid tumors. Adv Surg 28 (1995) 317-336
15. Reisine T., and Bell G.I. Molecular properties of somatostatin receptors. Neuroscience 67 4 (1995) 777-790
16. Patel Y.C. Somatostatin and its receptor family. Front Neuroendocrinol 20 3 (1999) 157-198
17. Bruns C., Weckbecker G., Raulf F., et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci 733 (1994) 138-146
18. Reubi J.C., Kappeler A., Waser B., et al. Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J Clin Endocrinol Metab 83 10 (1998) 3746-3749
19. Kimura N., Pilichowska M., Date F., et al. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 5 11 (1999) 3483-3487
20. Hofland L.J., and Lamberts S.W. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24 1 (2003) 28-47
21. Liebow C., Lee M.T., and Schally A. Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase. Metabolism 39 9 Supplement 2 (1990) 163-166
22. Pan M.G., Florio T., and Stork P.J. G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science 256 5060 (1992) 1215-1217
23. Schally A.V. Oncological applications of somatostatin analogues. Cancer Res 48 24 Pt 1 (1988) 6977-6985
24. Lamberts S.W., Krenning E.P., and Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12 4 (1991) 450-482
25. Cordelier P., Esteve J.P., Bousquet C., et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci U S A 94 17 (1997) 9343-9348
26. Todisco A., Seva C., Takeuchi Y., et al. Somatostatin inhibits AP-1 function via multiple protein phosphatases. Am J Physiol 269 1 Pt 1 (1995) G160-G166
27. Koizumi M., Onda M., Tanaka N., et al. Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 65 4 (2002) 200-206
28. Imam H., Eriksson B., Lukinius A., et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 36 6 (1997) 607-614
29. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102 1 (2004) 61-85
30. Bruns C., Lewis I., Briner U., et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146 5 (2002) 707-716
31. Hillman N., Herranz L., Alvarez C., et al. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes 106 3 (1998) 226-230
32. Vinik A., and Moattari A.R. Use of somatostatin analog in management of carcinoid syndrome. Digestive Diseases and Sciences 34 3 supplement (1989) 14S-27S
33. Kvols L.K., et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. The New England Journal of Medicine 315 11 (1986) 663-666
34. Tomassetti P., Migliori M., and Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 93 9 (1998) 1468-1471
35. Faiss S., Pape U.F., Bohmig M., et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 14 (2003) 2689-2696
36. Tomassetti P., Migliori M., Corinaldesi R., et al. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 14 5 (2000) 557-560
37. Ruszniewski P., et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39 2 (1996) 279-283
38. O'Toole D., Ducreux M., Bommelaer G., et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88 4 (2000) 770-776
39. Ricci S., Antonuzzo A., Galli L., et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 23 4 (2000) 412-415
40. Wymenga A.N., Eriksson B., Salmela P.I., et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17 4 (1999) 1111
41. Ruszniewski P., et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 80 4 (2004) 244-251
42. Eriksson B., and Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Annals of Oncology 10 supplement 2 (1999) S31-S38
43. Maton P.N. The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors. Gastroenterology Clinics of North America 18 4 (1989) 897-922
44. Arnold R., Trautmann M.E., Creutzfeldt W., et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38 3 (1996) 430-438
45. Scherubl H., et al. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. European Journal of Cancer 30A 10 (1994) 1590-1591
46. Ruskone A., et al. Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Digestive Diseases and Sciences 27 5 (1982) 459-466
47. O'Dorisio T.M., Mekhjian H.S., and Gaginella T.S. Medical therapy of VIPomas. Endocrinology and Metabolism Clinics of North America 18 2 (1989) 545-556
48. Santangelo W.C., et al. Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport. Annals of Internal Medicine 103 3 (1985) 363-367
49. Rosenbaum A., et al. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. Digestion 42 2 (1989) 116-120
50. Ch'ng J.L., et al. Growth hormone secretion dynamics in a patient with ectopic growth hormone-releasing factor production. The American Journal of Medicine 79 1 (1985) 135-138
51. Creutzfeldt W., et al. Pathomorphologic, biochemical, and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome). Human Pathology 6 1 (1975) 47-76
52. Ruszniewski P., et al. Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy. Pancreas 3 2 (1988) 145-152
53. Vinik A.I., et al. Somatostatin analogue (SMS 201-995) in patients with gastrinomas. Surgery 104 5 (1988) 834-842
54. Wulbrand U., et al. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. European Journal of Clinical Investigation 28 12 (1998) 1038-1049
55. Nauck C., et al. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors. Zeitschrift für Gastroenterologie 32 6 (1994) 323-327
56. Rubin J., et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology 17 2 (1999) 600-606
57. Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs 5 5 (1994) 503-519
58. Saltz L., Trochanowski B., Buckley M., et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72 1 (1993) 244-248
59. Panzuto F., Di Fonzo M., Iannicelli E., et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 17 3 (2006) 461-466
60. Faiss S., Scherubl H., Riecken E.O., et al. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res 142 (1996) 193-207
61. Welin S.V., Janson E.T., Sundin A., et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 151 1 (2004) 107-112
62. Faiss S., Rath U., Mansmann U., et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60 5 (1999) 469-476
63. Arnold R., Rinke A., Klose K.J., et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 3 8 (2005) 761-771
64. Hussaini S.H., Murphy G.M., Kennedy C., et al. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones. Gastroenterology 107 5 (1994) 1503-1513
65. Bigg-Wither G.W., Ho K.K., Grunstein R.R., et al. Effects of long term octreotide on gall stone formation and gall bladder function. Bmj 304 6842 (1992) 1611-1612
66. Trendle M.C., Moertel C.G., and Kvols L.K. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 79 4 (1997) 830-834
67. Plockinger U., Dienemann D., and Quabbe H.J. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 71 6 (1990) 1658-1662
68. Plockinger U., Perez-Canto A., Emde C., et al. Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly. Eur J Endocrinol 139 4 (1998) 387-394
69. Funa K., Eriksson B., Wilander E., et al. In situ hybridization study of chromogranin A and B mRNA in carcinoid tumors. Histochemistry 95 6 (1991) 555-559
70. Grander D., Oberg K., Lundqvist M.L., et al. Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet 336 8711 (1990) 337-340
71. Oberg K., and Eriksson B. The role of interferons in the management of carcinoid tumours. Br J Haematol 79 Supplement 1 (1991) 74-77
72. Oberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 3 1 (1992) 35-41
73. Oberg K., Eriksson B., and Janson E.T. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion 55 Supplement 3 (1994) 64-69
74. Detjen K.M., Welzel M., Farwig K., et al. Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 118 4 (2000) 735-748
75. Anderson P.M., Katsanis E., Leonard A.S., et al. Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res 50 6 (1990) 1853-1856
76. Dirix L.Y., Vermeulen P.B., Fierens H., et al. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors-an antiangiogenic effect?. Anticancer Drugs 7 2 (1996) 175-181
77. Andersson T., Wilander E., Eriksson B., et al. Effects of interferon on tumor tissue content in liver metastases of human carcinoid tumors. Cancer Res 50 11 (1990) 3413-3415
78. Brosjo O., Bauer H.C., Brostrom L.A., et al. Growth inhibition of human osteosarcomas in nude mice by human interferon-alpha: significance of dose and tumor differentiation. Cancer Res 47 1 (1987) 258-262
79. Biesma B., Willemse P.H., Mulder N.H., et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer 66 5 (1992) 850-855
80. Jacobsen M.B., Hanssen L.E., Kolmannskog F., et al. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scand J Gastroenterol 30 8 (1995) 789-796
81. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12 Supplement 2 (2001) S111-S114
82. Shah T., and Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 19 4 (2005) 617-636
83. Eriksson B., Oberg K., Alm G., et al. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet 2 8519 (1986) 1307-1309
84. Tiensuu Janson E.M., Ahlstrom H., Andersson T., et al. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28A 10 (1992) 1647-1650
85. Smith D.B., Scarffe J.H., Wagstaff J., et al. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep 71 12 (1987) 1265-1266
86. Doberauer C., Mengelkoch B., Kloke O., et al. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha. Acta Oncol 30 5 (1991) 603-605
87. Moertel C.G., Rubin J., and Kvols L.K. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7 7 (1989) 865-868
88. Creutzfeldt W., Bartsch H.H., Jacubaschke U., et al. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. Acta Oncol 30 4 (1991) 529-535
89. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 7 5 (1996) 453-463
90. Veenhof C.H., de Wit R., Taal B.G., et al. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour. Eur J Cancer 28 1 (1992) 75-78
91. Nobin A., Lindblom A., Mansson B., et al. Interferon treatment in patients with malignant carcinoids. Acta Oncol 28 3 (1989) 445-449
92. Ronnblom L.E., Alm G.V., and Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 30 4 (1991) 537-540
93. Nold R., Frank M., Kajdan U., et al. Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha. Z Gastroenterol 32 4 (1994) 193-197
94. Fjallskog M.L., Granberg D.P., Welin S.L., et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 5 (2001) 1101-1107
95. Aparicio T., Ducreux M., Baudin E., et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37 8 (2001) 1014-1019
96. di Bartolomeo M., Bajetta E., Buzzoni R., et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 2 (1996) 402-408
97. Arnold R., Neuhaus C., Benning R., et al. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg 17 4 (1993) 511-519
98. Arnold R., Benning R., Neuhaus C., et al. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 54 Suppl. 1 (1993) 72-75
99. Ducreux M., Ruszniewski P., Chayvialle J.A., et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95 11 (2000) 3276-3281
100. Eriksson B., Renstrup J., Imam H., et al. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 8 10 (1997) 1041-1044
101. Anthony L., Johnson D., Hande K., et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32 2 (1993) 217-223
102. Janson E.T., Ronnblom L., Ahlstrom H., et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 3 8 (1992) 635-638
103. Oberg K., Alm G., Magnusson A., et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 81 7 (1989) 531-535
104. Schober C., Schmoll E., Schmoll H.J., et al. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. Eur J Cancer 28A 10 (1992) 1664-1666